Trial Profile
B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic fatigue syndrome
- Focus Therapeutic Use
- Acronyms RituxME
- 02 Apr 2019 Status changed to completed as per results published in the Annals of Internal Medicine
- 02 Apr 2019 Primary endpoint (fatigue score: difference between treatment groups for repeated measurements of fatigue score (mean of 4-month intervals) through 24 months,) has not been met as per results published in the Annals of Internal Medicine
- 02 Apr 2019 Results published in the Annals of Internal Medicine